NEW YORK (360Dx) – Evercore ISI today upgraded its ratings for shares of Quest Diagnostics to Outperform from In Line, and raised the target price to $121 from $108, as tax changes and new insurance contracts are expected to lessen the impact of lower Medicare prices for lab tests under the Protecting Access to Medicare Act.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.